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Background: Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics. The aim of this pilot 
study was to assess the functional impact of cilostazol or clopidogrel adding on standard aspirin and clopidogrel treatment in T2DM patients and 
coronay artery disease undergoing percutaneous coronary intervention(PCI).
Methods: This was a prospective, double-blind, randomized, cross-over platelet function study. The cut-off value of clopidotrel resistance as 
expressed P2Y12 inhibition was below 20 % among patients with T2DM patients and coronay artery disease undergoing PCI. After PCI, T2DM patients 
on dual antiplatelet therapy were assigned to receive cilostazol 100 mg bid or clopidogrel 150mg for 28days and afterwards crossed-over treatment 
assignments for another 28 days. Platelet function test was performed at three time points: at baseline(T0), 28 days after randomization(T1), and 28 
days after treatment cross-over(T2). The P2Y12 inhibition(%) determined through VerifyNow testing was analyzed.
Results: A total of 34 T2DM patients were randomized into two groups (cilostazol adding vs clopidogrel doubling) ; 2 patients discontinued 
treatment due to side effects. The clopidogrel resistance expressed as P2Y12 inihbition was significantly improved following cilostazol treatment or 
clopidogrel doubling treatment compared with pretreatments and this effects continued after cross-over (figure1.P2Y12 inhibition determined by the 
VerifyNow P2Y12 assay. P2Y12 inhibition values are expressed as percentage (%)).
Conclusions: Adjunctive treatment with cilostazol in T2DM patients on standard dual antiplatelet therapy might be a strategy for overcoming 
clopidotrel resistance
